Newsroom | 5509 results

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson showcases new clinical data for TECNIS PureSee IOL demonstrating excellent contrast sensitivity and extended range of vision...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for the first quarter ended April 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement because it expects to be interacting with members of the investment community, as well as with surgeons and other members of t...

DURHAM, N.C.--(BUSINESS WIRE)--Sightview will offer early demo access to its new flagship EHR platform at the 2026 ASCRS Annual Meeting....

AUSTIN, Texas--(BUSINESS WIRE)--Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases, today announced that Company management will participate in the private company tracks of two upcoming investor conferences. Piper Sandler Biopharma Symposium 1x1 Meetings: Wednesday, April 15, 2026 Location: Boston, MA UBS Private Biotech Summit 1x1 Meetings: Monday, May 18, 2026 Location: New York, NY About Ollin Biosciences Established...

SEATTLE & CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Aurion Biotech, Inc. (“Aurion Biotech”), a commercial-stage regenerative cell therapy company dedicated to restoring vision and working toward a future where blindness is eliminated, today announced that the first patients have been dosed in the U.S. ASTRA Phase 3 pivotal study of AURN001, a single-administration regenerative cell therapy for corneal edema secondary to corneal endothelial dysfunction. AURN001 has the potential to be the first...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release first quarter 2026 financial results after the market close on Wednesday, April 29, 2026. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on April 29, 2026. A link to t...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Bi-Blade+ advanced dual-port vitrectomy cutter and the Adaptive Fluidics advanced update on the Stellaris Elite® Vision Enhancement System. “Retinal surgeons who are familiar with our Bi-Blade technology understand the benefits of it...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et du système nerveux central, publie aujourd’hui sa situation de trésorerie et les revenus de son programme d’Autorisation d’Accès Compassionnel (AAC) au 31 mars 2026. Situation de trésorerie au 31 mars 2026 La trésoreri...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position and the revenues from its Named Patient Early Access Program as of March 31, 2026. Cash position as of March 31, 2026 GenSight Biologics’ cash and cash equivalents totaled €3.2 million...

TORONTO--(BUSINESS WIRE)--Cette saison, Alcon, le chef de file mondial en matière de soins oculaires qui se consacre à aider les gens à voir avec clarté, a annoncé un partenariat entre les Blue Jays de Toronto et SystaneMD en tant que gouttes oculaires officielles de l’équipe. Le partenariat vise à aider les Canadiens à reconnaître les signes de la sécheresse oculaire et à regarder chaque partie dans le plus grand confort. Pour les 8,5 millions de Canadiens aux prises avec la sécheresse oculair...